Alkaline Phosphatase, Bilirubin Predict Outcomes in PBC

This article originally appeared here.
Share this content:
Alkaline Phosphatase, Bilirubin Predict Outcomes in PBC
Alkaline Phosphatase, Bilirubin Predict Outcomes in PBC

TUESDAY, Dec. 30, 2014 (HealthDay News) -- For patients with primary biliary cirrhosis (PBC), levels of alkaline phosphatase and bilirubin predict clinical outcome, according to a meta-analysis published in the December issue of Gastroenterology.

Willem J. Lammers, M.D., from the Erasmus University Medical Center in Rotterdam, Netherlands, and colleagues performed a meta-analysis of individual patient data from 4,845 patients with PBC in 15 cohort studies. The authors examined the correlation between levels of alkaline phosphatase and bilirubin and outcomes.

The researchers found that 1,118 patients reached a clinical end point. There was a strong correlation between levels of alkaline phosphatase and bilirubin measured at study enrollment and each year for five years and clinical outcomes (lower levels correlated with longer transplant-free survival). The best prediction of patient outcome was seen for levels of alkaline phosphatase that were 2.0 times the upper limit of normal (ULN) at one year after study enrollment (C-statistic, 0.71), but this was not significantly better than other thresholds. A bilirubin level 1.0 times the ULN at one year after study enrollment best predicted patient transplant-free survival (C-statistic, 0.79). The ability to predict patient survival times was increased by combining levels of alkaline phosphatase and bilirubin.

"Levels of alkaline phosphatase and bilirubin can predict outcomes (liver transplantation or death) of patients with PBC and might be used as surrogate end points in therapy trials," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry; the study was partially funded by Intercept Pharmaceuticals and Zambon Nederland BV.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »